MarketCap
Facebook
X
TelegramQuarterly report 2022-Q2
added 08-09-2022
Epizyme Deferred Revenue 2011-2025 | EPZM
Deferred revenue is the amount of money or obligations that a company has received in advance for goods or services that have not yet been delivered or performed. In other words, it is income that has already been received but has not yet been recognized in accounting as revenue because the goods or services have not yet been transferred to the customer.Features of the metric
- Sources of future cash inflows
A high level of deferred revenue indicates that the company has secured future cash flows, which positively affects forecasts of its financial condition and stability. - Assessment of operational stability
Deferred revenue reflects demand for the company’s products or services and its ability to attract customers willing to pay in advance. It is one of the indicators of business stability and its competitive advantages. - Risks and obligations
Although deferred revenue indicates future inflows, it also represents obligations that the company must fulfill. If fulfilling these obligations is delayed or impossible, it can negatively impact reputation and financial results. - Analysis of liquidity and cash flow
Inflows in the form of deferred revenue improve the company’s current liquidity since the funds are already in the accounts. However, investors need to assess the ratio of deferred revenue to fulfilled obligations to understand the actual financial capabilities and risks. - Impact on company valuation
In fundamental analysis, deferred revenue is taken into account for accurate revenue and profit forecasting, especially in industries with long-term contracts or subscriptions (e.g., IT sector, services, manufacturing).
Annual Deferred Revenue Epizyme
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | 13.3 M | - | - | 1.9 M | 1.7 M | 23.2 M | 28.2 M | 7.1 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 28.2 M | 1.7 M | 12.6 M |
Quarterly Deferred Revenue Epizyme
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | 5 M | - | - | - | - | - | 1.79 M | 6.26 M | 5.41 M | 13.3 M | 13.3 M | 13.3 M | 13.3 M | - | - | - | - | - | 478 K | 956 K | 1.43 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.7 M | 1.7 M | 1.7 M | 1.7 M | 23.2 M | 23.2 M | 23.2 M | 23.2 M | 28.2 M | 28.2 M | 28.2 M | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 28.2 M | 478 K | 10.3 M |
Deferred Revenue of other stocks in the Biotechnology industry
| Issuer | Deferred Revenue | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Alpine Immune Sciences
ALPN
|
35.6 M | - | - | $ 2.17 B |  USA |
 |
Arbutus Biopharma Corporation
ABUS
|
11.8 M | $ 4.75 | 1.61 % | $ 788 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
3.89 M | $ 3.29 | -2.08 % | $ 254 M | USA |
 |
AlloVir
ALVR
|
2.66 M | - | 4.14 % | $ 49.1 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
643 K | $ 25.32 | -2.24 % | $ 1.23 B | USA |
 |
Adaptimmune Therapeutics plc
ADAP
|
29 M | - | -15.15 % | $ 60.3 M |  Britain |
 |
Ampio Pharmaceuticals
AMPE
|
85.7 K | - | -11.43 % | $ 502 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
517 K | - | - | $ 1.01 B | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
15.9 M | - | - | $ 40.3 B | USA |
 |
Ascendis Pharma A/S
ASND
|
363 K | $ 209.8 | -0.17 % | $ 5 B |  Danmark |
 |
Alterity Therapeutics Limited
ATHE
|
33.3 K | $ 3.34 | -2.47 % | $ 8.04 B |  Australia |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.69 M | - | -1.52 % | $ 24.7 M | USA |
 |
Anika Therapeutics
ANIK
|
24.5 K | $ 9.55 | 0.58 % | $ 140 M | USA |
 |
Brickell Biotech
BBI
|
1.8 M | - | -5.38 % | $ 6.06 M | USA |
 |
BeiGene, Ltd.
BGNE
|
187 M | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Bellicum Pharmaceuticals
BLCM
|
2.98 M | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
9.09 M | - | -7.31 % | $ 87 M | USA |
 |
Aytu BioScience
AYTU
|
339 K | $ 2.35 | 3.0 % | $ 14.8 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
1.11 M | - | -6.81 % | $ 3.04 B | USA |
 |
ChromaDex Corporation
CDXC
|
278 K | - | -0.88 % | $ 598 M | USA |
 |
Axon Enterprise
AXON
|
613 M | $ 568.91 | -2.09 % | $ 43.1 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
405 K | $ 0.28 | -2.28 % | $ 609 M |  Israel |
 |
Catalyst Biosciences
CBIO
|
39 K | $ 14.62 | -4.54 % | $ 962 M | USA |
 |
Cerus Corporation
CERS
|
1.4 M | $ 2.19 | 1.63 % | $ 404 M | USA |
 |
Caladrius Biosciences
CLBS
|
5.1 M | - | -16.75 % | $ 25.8 M | USA |
 |
Biogen
BIIB
|
55.7 M | $ 174.71 | 1.28 % | $ 25.4 B | USA |
 |
BioNTech SE
BNTX
|
300 M | $ 94.91 | -1.14 % | $ 27.2 B |  Germany |
 |
Eloxx Pharmaceuticals
ELOX
|
403 K | - | -5.68 % | $ 8.28 M | USA |
 |
Acer Therapeutics
ACER
|
2.91 M | - | 2.71 % | $ 14 M | USA |
 |
Acorda Therapeutics
ACOR
|
227 K | - | -24.86 % | $ 820 K | USA |